Raymond James & Associates cut its stake in Calumet Specialty Products Partners, LP (NASDAQ: CLMT – Get Rating) by 14.0% in the 3rd quarter, according to company data released in its latest 13F filing with the Securities and Exchange Commission and exchanges. The firm owned 306,832 shares of the oil and gas company after selling 50,102 shares during the period. Raymond James & Associates owned approximately 0.39% of Calumet Specialty Products Partners, valued at $3,931,000 at the end of the most recent quarter.
→ Profits from the commercial solar boom? (from investment trends)
Other institutional investors and hedge funds have also bought and sold shares in the company. UBS Group AG increased its stake in Calumet Specialty Products Partners by 3.4% during the 1st quarter. UBS Group AG currently owns 97,580 shares of the oil and gas company valued at $1,328,000 after acquiring an additional 3,211 shares during the period. PEAK6 Investments LLC increased its stake in Calumet Specialty Products Partners by 152.9% in the 1st quarter. PEAK6 Investments LLC now owns 70,757 shares in the oil and gas company worth $963,000 after acquiring an additional 42,784 shares during the period. Citigroup Inc. increased its stake in Calumet Specialty Products Partners by 185.7% in the 1st quarter. Citigroup Inc. currently holds 25,289 shares in an oil and gas company valued at $344,000 after acquiring an additional 16,436 shares during the period. Atria Wealth Solutions Inc. acquired a new equity stake in Calumet Specialty Products Partners in the 2nd quarter for $208,000. Finally, Advisor Group Holdings Inc. increased its stake in Calumet Specialty Products Partners by 24.6% in the 1st quarter. Advisor Group Holdings Inc. currently holds 11,796 shares in an oil and gas company valued at $160,000 after acquiring an additional 2,329 shares during the period. 21.05% of the shares are currently held by institutional investors and hedge funds.
Dynamics of shares of Calumet Specialty Products partners
Shares of NASDAQ CLMT opened Thursday at $16.81. The firm has a market capitalization of $1.33 billion, a PE of -7.44, and a beta of 2.12. The firm has a fifty-day moving average of $15.71 and a 200-day moving average of $15.39. Calumet Specialty Products Partners, LP has an annual minimum of $8.40 and an annual maximum of $20.50.
Calumet Specialty Products Partners (NASDAQ: CLMT – Get Rating) last released its financial results on Wednesday, November 9th. The oil and gas company reported earnings per share (EPS) of $0.59 for the quarter, beating analysts’ consensus estimate of $0.46 by $0.13. The business’s revenue for the quarter was $1.17 billion, while analysts had expected $1.08 billion. On average, analysts forecast Calumet Specialty Products Partners, LP to earn 0.63 earnings per share for the current fiscal year.
Insider trading at Calumet Specialty Products Partners
In other Calumet Specialty Products Partners news, director James S. Carter bought 2,000 shares of the company in a deal dated Monday, Nov. 28. The shares were purchased at an average price of $16.18 per share for a total value of $32,360.00. With the completion of the acquisition, the director now directly owns 289,283 shares of the company worth $4,680,598.94. The deal was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, director James S. Carter purchased 2,000 shares of the company in a transaction that took place on Monday, November 28th. The shares were purchased at an average price of $16.18 per share for a total value of $32,360.00. With the completion of the acquisition, the director now owns 289,283 shares of the company, worth approximately $4,680,598.94. The transaction was disclosed in a document filed with the Securities and Exchange Commission, which can be accessed at this hyperlink. In addition, Chairman Stephen P. Maver purchased 3,500 shares of the company in a transaction that took place on Monday, November 21st. The shares were purchased at an average price of $16.27 per share for a total value of $56,945.00. Following the acquisition, the chairman now directly owns 150,054 shares of the company, worth approximately $2,441,378.58. Disclosure information about this purchase can be found here. Insiders have purchased 9,500 shares of the company worth $160,765 in the past 90 days. 2.91% of the shares are currently held by corporate insiders.
Wall Street Analysts Predict Growth
Several equity analysts have recently released reports on CLMT shares. UBS Group began covering Calumet Specialty Products Partners stock in a research note on Tuesday, December 13th. They gave the company a “neutral” rating and a target price of $15.70. StockNews.com upgraded Calumet Specialty Products Partners stock to Hold from a Sell rating in a research note on Thursday, November 17th. Two analysts gave the stock a Hold rating and four gave it a Buy rating. The company currently has a Moderate Buy consensus rating and an average price target of $23.14, according to MarketBeat.com.
About Calumet Specialty Products Partners
(Get ranked)
Calumet Specialty Products Partners, LP manufactures, formulates and markets a range of speciality brand products in a variety of consumer and industrial markets in North America and internationally. The Specialty Products and Solutions segment offer a variety of solvents, waxes, personal lubricating oils, white oils, petrolatums, gels, esters and other products.
Featured Stories
Want to know what other hedge funds own CLMT? Visit HoldingsChannel.com for the latest 13F documents and insider trading for Calumet Specialty Products Partners, LP (NASDAQ: CLMT – Get Ranked).
This instant news alert was created using MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reporting. This story has been reviewed by MarketBeat before publishing. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider partnering with Calumet Specialty Products, you need to hear this.
MarketBeat tracks Wall Street’s most popular and effective analysts daily and the stocks they recommend to their clients. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the wider market takes notice… and Calumet Specialty Products Partners was not on the list.
While Calumet Specialty Products Partners currently has a Moderate Buy rating among analysts, the top-rated analysts believe these five stocks are better buys.
View five promotions here